Author name: Zach Galati

Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with SMA, offering a one-time gene replacement therapy option. The update also includes ongoing engagement opportunities with the SMA community, upcoming ITVISMA webinars, Adaptive Sports and Recreation resources from Cure SMA, […]

Genentech recently released an update on their continued collaboration with the SMA community and Evrysdi® tablet updates. They will continue to provide timely updates as they become available. Read the full community update letter here. “Looking back, 2025 was a time that was undeniably defined as a year of great change. We successfully navigated shifts,

Earlier this year, Cure SMA launched an expanded Phase 10 of the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, SMA Europe, Cure SMA, and other nonprofit organizations to share information, ideas, and data to benefit the broader SMA community. Through the Industry Collaboration, we fund projects to ensure